A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
FAST NEWS: Simcere Pharma New Co-CEO Sends Investors Scurrying
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced late Wednesday that executive director Tang Renhong has been appointed as Co-CEO and will assist Chairman and CEO Ren Jinsheng in leading…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.
Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87%…
Kintor Pharma Gets Mega-Booster from Experimental Covid-19 Drug
Company posted major milestone last week with the first emergency use authorization for its drug Proxalutamide to treat the coronavirus in Paraguay Key points: Kintor Pharma’s Proxalutamide could become a…
Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock
Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled…